Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00727857 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

A Phase 3 study of Diabetes Mellitus, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
600
Enrollment target
20
Study locations

NCT00727857: Completed Phase 3 study of Diabetes Mellitus, sponsored by Takeda.

NCT00727857 is a Phase 3 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 600 participants, below the 1,865-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00727857, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
600 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Type 2 Diabetes Mellitus.

Primary Outcome

The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline.

Conditions Studied

Diabetes Mellitus

Interventions

  • DRUG Metformin
  • DRUG Pioglitazone
  • DRUG Pioglitazone and metformin

Study Locations (20)

California

  • - Anaheim
  • - Artesia
  • - Dinuba
  • - Long Beach
  • - Los Angeles
  • - Norwalk
  • - Orange
  • - Santa Ana
  • - Santa Monica

Alabama

  • - Birmingham
  • - Haleyville
  • - Montgomery
  • - Pell City

Florida

  • - Altamonte Springs
  • - Coral Gables
  • - Hialeah
  • - Miami

Arizona

  • - Phoenix
  • - Tucson

Colorado

  • - Pueblo

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2007-06
Est. Completion 2008-08
Phase Phase 3
Takeda

408 total trials

What the finished NCT00727857 record still lists

NCT00727857 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 1,865-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (68% lower).

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.

NCT00727857 names 20 study sites across 5 states, led by California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT00727857 about?

NCT00727857 is a clinical study titled "Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.". The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Type 2 Diabetes Mellitus.

What is the current status of trial NCT00727857?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2007-06. Estimated completion is 2008-08.

What conditions does trial NCT00727857 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT00727857?

The interventions under investigation include: Metformin (DRUG), Pioglitazone (DRUG), Pioglitazone and metformin (DRUG).

Who is sponsoring clinical trial NCT00727857?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00727857 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00727857's enrollment target sits among peer trials

600 40th of 208 higher than 169 of 208 other Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00727857, the US trial registry maintained by the National Library of Medicine. NCT00727857 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.